A neuroscientist with a specialty in amyotrophic lateral sclerosis (ALS) is joining the faculty at Vanderbilt University Medical Center (VUMC) and will establish an ALS research center at the Nashville school. Véronique Belzil, PhD, whose work is focused on developing tailored treatments for people with ALS, also will serve…
News
Scientists have created new “molecular traps” that were able to improve survival in cell and fruit fly models of amyotrophic lateral sclerosis (ALS) associated with mutations in the gene C9ORF72. The traps bind to the toxic small proteins that arise from the mutated C9ORF72 gene and have a harmful…
The U.S. Food and Drug Administration (FDA) soon will meet with BrainStorm Cell Therapeutics to discuss the company’s plans for a confirmatory Phase 3b trial of NurOwn in people with amyotrophic lateral sclerosis (ALS). The expedited, face-to-face meeting is scheduled for Dec. 6, less than two months…
A partnership between LifeArc and the UK Dementia Research Institute (UK DRI) is awarding £14.5 million (about $18.2 million) to seven research projects aimed at developing new tests, treatments, and devices for neurodegenerative diseases. “Our partnership with UK DRI allows us to identify and back the most promising translational…
Toxic compounds produced by cyanobacteria, which have been identified as risk factors for developing amyotrophic lateral sclerosis (ALS), were detected in air and earth samples collected around the Great Salt Lake in Utah, a study reports. “An understanding of the types and concentrations of cyanotoxins present in air is…
VectorY Therapeutics has raised about $138 million in funding aiming to bring into clinical testing VTx-002, its lead treatment candidate for amyotrophic lateral sclerosis (ALS). The therapy equips nerve cells to produce antibodies against the damaging TDP-43 protein clumps that are an ALS hallmark. “The investment…
SOL-257, an experimental one-time gene therapy, was well tolerated and significantly improved disease outcomes in two distinct mouse models of amyotrophic lateral sclerosis (ALS). Developed by Sola Biosciences, SOL-257 is designed to clear the toxic TDP-43 protein that accumulates and forms clumps in ALS nerve cells, contributing to…
The U.S. Food and Drug Administration (FDA) has signed off on the chemistry, manufacturing, and controls (CMC) clinical development plan for NeuroSense Therapeutics‘ lead candidate for amyotrophic lateral sclerosis (ALS) ahead of a planned Phase 3 study. The Phase 3 trial of PrimeC is due to start…
Pasithea Therapeutics has selected a lead candidate for its PAS-003 program, which is intended to target a “velcro-like” protein to treat amyotrophic lateral sclerosis (ALS). The new therapy is a humanized monoclonal antibody that potently inhibits the alpha-5/beta-1 integrin protein. It was selected after extensive screening and characterization studies…
Two Canadian provinces — Prince Edward Island, and Newfoundland and Labrador — are covering the cost of the oral formulation of Radicava (edaravone) for eligible residents with amyotrophic lateral sclerosis (ALS). Patients will have access through their provincial drug plans to Radicava Oral Suspension, developed along with…
Recent Posts
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.
- MDA launches Shamrocks fundraiser to advance neuromuscular research
- Early-career ALS scientist wins first MDA Research Momentum Award